Jett Travolta and Kawasaki Disease: Separating Fact From Fiction
Posted on: Monday, 5 January 2009, 10:08 CST
Vasculitis is a family of potentially life-threatening diseases of unknown cause linked by blood vessel inflammation and an overactive immune system. Left untreated, most types of vasculitis can cause serious organ/tissue damage and may lead to death. Currently there is no cure, but proper and early treatment allows most individuals to live near normal lives.
About the Vasculitis Foundation
The VF is the international organization for patients with vasculitis. There is no known cause or cure for vasculitis. Early diagnosis and effective treatment are critical for patients. Through its website, educational materials, medical consultants, symposia, chapters and support groups the VF strives to educate and support patients, family members and medical professionals. The VF Research Program has funded over
The VF was established to alleviate the isolation that patients and families experience when these rare life-threatening diseases affect them. The VF strives to improve the lives of vasculitis patients around the world. For more information: www.Vasculitisfoundation.org
SOURCE Vasculitis Foundation
Source: PR Newswire
Related Articles
- US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
- California Association of Health Plans & California Medical Association Foundation Team Up to Combat Obesity
- Biorx Pledges Long-Term Financial Commitment to Patients With Primary Immunodeficiency Diseases and the Immune Deficiency Foundation
- Positive Findings From Clinical Studies of QUADRAMET(R) in Prostate Cancer Patients With Metastatic Bone Disease Presented at ASCO Prostate Cancer Symposium
- Oklahoma Medical Research Foundation Study Seeks Healthy Women
- Oklahoma Medical Research Foundation Receives $1.8M Award
- Oklahoma Medical Research Foundation Scientists Receive $8 M to Study Flu Vaccine
- Infections of Febrile Neutropenic Patients in Malignant Hematological Diseases (Second Study Period)
- Pfizer's Norvasc Demonstrates Significant Reductions in Major Cardiovascular Events in Patients With Coronary Artery Disease
- Actelion Ltd.: New Scientific Studies Show Higher Than Expected Prevalence of Pulmonary Arterial Hypertension in Patients With Connective Tissue Diseases (CTD)
User Comments (0)

RSS Feeds